[go: up one dir, main page]
Skip to main content

Advertisement

SpringerLink
Log in

Inflammation: The Link Between Obesity and Cardiovascular Risk

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

It is now clear that adipose tissue is more than just an area for fat storage, as suggested by a large body of recent literature. Fat, in particular abdominal depots, is an active source of biological mediators, which affect metabolic pathways and vascular function. These effects seem to be in part related to inflammation, especially in the pathogenesis and progression of atherosclerosis. As cardiovascular pathology, in particular coronary artery disease, still represents one of the main causes of morbidity and mortality in Western countries, the need for markers to make a correct risk stratification of patients is rising with the increasing complexity of treatment strategies now available. Thus, molecules produced by adipose tissue, known as adipocytokines, have been studied largely for their potential use as biomarkers both in primary and secondary prevention. The aim of this article is to examine recent evidence about the main adipocytokines, including leptin, adiponectin, resistin, and C-reactive protein, of which adipose tissue an important source.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105:2696–2698.

    Article  PubMed  Google Scholar 

  2. Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34.

    CAS  PubMed  Google Scholar 

  3. Calabrò P, Limongelli G, Pacileo G, et al.: The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown) 2008, 9:450–460.

    Google Scholar 

  4. Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023–1033.

    Article  CAS  PubMed  Google Scholar 

  5. • Calabrò P, Golia E, Maddaloni V, et al.: Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 2009, 4:25–34. This is recent review on the molecular mechanisms linking adipose tissue, inflammation, and cardiovascular diseases.

    Article  PubMed  Google Scholar 

  6. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.

    CAS  PubMed  Google Scholar 

  7. Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112–1113.

    Article  CAS  PubMed  Google Scholar 

  8. Calabro P, Chang DW, Willerson JT, Yeh ET: Production of C-reactive protein and serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur Heart J 2005, 26:334–335.

    Google Scholar 

  9. Cousin B, Munoz O, Andre M, et al.: A role for preadipocytes as macrophage-like cells. FASEB J 1999, 13:305–312.

    CAS  PubMed  Google Scholar 

  10. Braunwald E: Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360–1369.

    Article  CAS  PubMed  Google Scholar 

  11. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898–904.

    Article  PubMed  Google Scholar 

  12. Greenland P, Knoll MD, Stamler J, et al.: Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891–897.

    Article  PubMed  Google Scholar 

  13. Canto JG, Iskandrian AE: Major risk factors for cardiovascular disease: debunking the “only 50%” myth. JAMA 2003, 290:947.

    Article  PubMed  Google Scholar 

  14. Chu NF, Spiegelman D, Hotamisligil GS, et al.: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001, 157:495–503.

    Article  CAS  PubMed  Google Scholar 

  15. Donahue RP, Prineas RJ, Donahue RD, et al.: Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999, 22:1092–1096.

    Article  CAS  PubMed  Google Scholar 

  16. Leyva F, Godsland IF, Ghatei M, et al.: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18:928–933.

    CAS  PubMed  Google Scholar 

  17. Zimmet PZ, Collins VR, de Courten MP, et al., on behalf of Mauritius NCD Study Group: Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Int J Obes Relat Metab Disord 1998, 22:171–177.

    Article  CAS  PubMed  Google Scholar 

  18. Soderberg S, Ahren B, Jansson JH, et al.: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999, 246:409–418.

    Article  CAS  PubMed  Google Scholar 

  19. Wallace AM, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.

    Article  CAS  PubMed  Google Scholar 

  20. Wolk R, Berger P, Lennon RJ, et al.: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44:1819–1824.

    Article  CAS  PubMed  Google Scholar 

  21. Lawlor DA, Davey Smith G, Kelly A, et al.: Leptin and coronary heart disease risk: prospective case control study of British women. Obesity (Silver Spring) 2007, 15:1694–1701.

    Article  CAS  Google Scholar 

  22. Sattar N, Wannamethee G, Sarwar N, et al.: Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009, 53:167–175.

    Article  CAS  PubMed  Google Scholar 

  23. Amasyali B, Aytemir K, Kose S, et al.: Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction. Angiology 2006 57:671–680.

    Article  CAS  PubMed  Google Scholar 

  24. Söderberg S, Colquhoun D, Keech A, et al.; LIPID Study Investigators: Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 2009, 33:123–130.

    Article  Google Scholar 

  25. Karakas M, Zierer A, Herder C, et al.: Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984–2002. Atherosclerosis 2009 Aug 20 [epub ahead of print].

  26. Sharma AM: Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002, 26(Suppl 4):S5–S7.

    Article  CAS  PubMed  Google Scholar 

  27. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.

    CAS  PubMed  Google Scholar 

  28. Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.

    Article  CAS  PubMed  Google Scholar 

  29. Maahs DM, Ogden LG, Kinney GL, et al.: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747–753.

    Article  CAS  PubMed  Google Scholar 

  30. Wolk R, Berger P, Lennon RJ, et al.: Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292–298.

    Article  CAS  PubMed  Google Scholar 

  31. Liang KW, Sheu WH, Lee WL, et al.: Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol 2008, 129:76–80.

    Article  PubMed  Google Scholar 

  32. Sattar N, Wannamethee G, Sarwar N, et al.: Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623–629. (Published erratum appears in Circulation 2007, 115:e325.)

    Article  CAS  PubMed  Google Scholar 

  33. Lawlor DA, Davey Smith G, Ebrahim S, et al.: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677–5683.

    Article  CAS  PubMed  Google Scholar 

  34. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C: Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009, 10:269–279.

    Article  CAS  PubMed  Google Scholar 

  35. Zhang MH, Spies C, Ali S, et al.: Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis. 2009, 205:233–238.

    Article  CAS  PubMed  Google Scholar 

  36. Rathmann W, Haastert B, Herder C, et al.: Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond) 2007, 31:770–776.

    CAS  Google Scholar 

  37. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al.: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452–5455.

    Article  CAS  PubMed  Google Scholar 

  38. Azuma K, Katsukawa F, Oguchi S, et al.: Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11:997–1001.

    Article  CAS  PubMed  Google Scholar 

  39. Lee JH, Chan JL, Yiannakouris N, et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848–4856.

    Article  CAS  PubMed  Google Scholar 

  40. Utzschneider KM, Carr DB, Tong J, et al.: Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330–2333.

    Article  CAS  PubMed  Google Scholar 

  41. Gomez-Ambrosi J, Fruhbeck G: Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001, 135:306–307.

    CAS  PubMed  Google Scholar 

  42. Ohmori R, Momiyama Y, Kato R, et al.: Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379–380.

    Article  PubMed  Google Scholar 

  43. Reilly MP, Lehrke M, Wolfe ML, et al.: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932–939.

    Article  CAS  PubMed  Google Scholar 

  44. Pischon T, Bamberger CM, Kratzsch J, et al.: Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764–1771.

    Article  CAS  PubMed  Google Scholar 

  45. Pilz S, Weihrauch G, Seelhorst U, et al.: Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxford) 2007, 66:380–386.

    Article  Google Scholar 

  46. Lubos E, Messow CM, Schnabel R, et al.: Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193:121–128.

    Article  CAS  PubMed  Google Scholar 

  47. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al.: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxford) 2005, 62:242–249.

    Article  CAS  Google Scholar 

  48. Weikert C, Westphal S, Berger K, et al.: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. Clin Endocrinol Metab 2008, 93:2647–2653.

    Article  CAS  Google Scholar 

  49. • Calabrò P, Golia E, Yeh ET: CRP and the risk of atherosclerotic events. Semin Immunopathol 2009, 31:79–94. This is a recent review on CRP and the risk of cardiovascular events, both on the molecular and clinical level.

    Article  PubMed  Google Scholar 

  50. Memoli B, Procino A, Calabrò P, et al.: Inflammation may modulate interleukin 6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am J Physiol Endocrinol Metab 2007, 293:E1030–E1035.

    Article  CAS  PubMed  Google Scholar 

  51. Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671–674.

    Article  CAS  PubMed  Google Scholar 

  52. Anty R, Bekri S, Luciani N, et al.: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 2006, 101:1824–1833.

    Article  CAS  PubMed  Google Scholar 

  53. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979. (Published erratum appears in N Engl J Med 1997, 337:356.)

    Article  CAS  PubMed  Google Scholar 

  54. • Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611–619. (Published erratum appears in JAMA 2007, 297:1433). This article proposed a novel algorithm for the assessment of cardiovascular risk, including inflammation as reflected by CRP levels.

    Article  CAS  PubMed  Google Scholar 

  55. Ridker PM, Paynter NP, Rifai N, et al.: C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008, 118:2243–2251.

    Article  CAS  PubMed  Google Scholar 

  56. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.

    Article  PubMed  Google Scholar 

  57. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.

    Article  CAS  PubMed  Google Scholar 

  58. Sinning JM, Bickel C, Messow CM, et al.: Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006, 27:2962–2968.

    Article  CAS  PubMed  Google Scholar 

  59. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC: Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009, 204:239–243.

    Article  CAS  PubMed  Google Scholar 

  60. Hoffmann R, Suliman H, Haager P, et al.: Association of C-reactive protein and myocardial perfusion in patients with ST elevation acute myocardial infarction. Atherosclerosis 2006, 186:177–183.

    Article  CAS  PubMed  Google Scholar 

  61. Nakachi T, Kosuge M, Hibi K, et al.: C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J 2008, 72:1953–1959.

    Article  CAS  PubMed  Google Scholar 

  62. Bogaty P, Boyer L, Simard S, et al.: Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (Recurrence and Inflammation in Acute Coronary Syndromes) study. J Am Coll Cardiol 2008, 51:2339–2346.

    Article  CAS  PubMed  Google Scholar 

  63. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444:860–867.

    Article  CAS  PubMed  Google Scholar 

  64. Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131–2135.

    Article  CAS  PubMed  Google Scholar 

  65. Patel SB, Reams GP, Spear RM, et al.: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008, 10:131–137.

    Article  CAS  PubMed  Google Scholar 

  66. Spalding KL, Arner E, Westermark PO, et al.: Dynamics of fat cell turnover in humans. Nature 2008, 453:783–787.

    Article  CAS  PubMed  Google Scholar 

  67. Goodpaster BH, Kelley DE, Wing RR, et al.: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839–847.

    Article  CAS  PubMed  Google Scholar 

  68. Donnelly JE, Hill JO, Jacobsen DJ, et al.: Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial. Arch Intern Med 2003, 163:1343–1350.

    Article  PubMed  Google Scholar 

  69. Racette SB, Weiss EP, Villareal DT, et al.: One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol Ser A Biol Sci Med Sci 2006, 61:943–950.

    Google Scholar 

  70. Larson-Meyer DE, Heilbronn LK, Redman LM, et al.: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006, 29:1337–1344.

    Article  PubMed  Google Scholar 

  71. Varady KA, Tussing L, Bhutani S, Braunschweig CL: Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009, 58:1096–1101.

    Article  CAS  PubMed  Google Scholar 

  72. Madsen EL, Rissanen A, Bruun JM, et al.: Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008, 158:179–187.

    Article  CAS  PubMed  Google Scholar 

  73. Selvin E, Paynter NP, Erlinger TP: The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31–39.

    Article  CAS  PubMed  Google Scholar 

  74. Bougoulia M, Triantos A, Koliakos G: Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006, 5:259–269.

    Google Scholar 

  75. Heilbronn LK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001, 21:968–970.

    CAS  PubMed  Google Scholar 

  76. O’Brien KD, Brehm BJ, Seeley RJ, et al.: Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005, 90:2244–2249.

    Article  PubMed  Google Scholar 

  77. You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004, 89:1739–1746. (Published erratum appears in J Clin Endocrinol Metab 2004, 89:2972.)

    Article  CAS  PubMed  Google Scholar 

  78. Forsythe LK, Wallace JM, Livingstone MB: “Obesity and inflammation: the effects of weight loss.”. Nutr Res Rev 2008, 21:117–133.

    Article  CAS  PubMed  Google Scholar 

  79. Wood RJ, Volek JS, Davis SR, et al.: Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (London) 2006, 3:19.

    Article  Google Scholar 

  80. Noakes M, Keogh JB, Foster PR, Clifton PM: Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005, 81:1298–1306.

    CAS  PubMed  Google Scholar 

  81. Pereira MA, Swain J, Goldfine AB, et al.: Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004, 292:2482–2490.

    Article  CAS  PubMed  Google Scholar 

  82. Rokling-Andersen MH, Reseland JE, Veierød MB, et al.: Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr 2007, 86:1293–1301.

    CAS  PubMed  Google Scholar 

  83. Olson TP, Dengel DR, Leon AS, Schmitz KH: Changes in inflammatory biomarkers following one-year of moderate resistance training in overweight women. Int J Obes (London) 2007, 31:996–1003.

    Article  CAS  Google Scholar 

  84. Okita K, Nishijima H, Murakami T, et al.: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004, 24:1868–1873.

    Article  CAS  PubMed  Google Scholar 

  85. Busetto L, Bassetto F, Zocchi M, et al.: The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. Nutr Metab Cardiovasc Dis 2008, 18:112–120.

    Article  CAS  PubMed  Google Scholar 

  86. Laimer M, Ebenbichler CF, Kaser S, et al.: Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 2002, 26:659–662.

    Article  CAS  PubMed  Google Scholar 

  87. Vázquez LA, Pazos F, Berrazueta JR, et al.: Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005, 90:316–322.

    Article  PubMed  Google Scholar 

  88. Gavrila A, Peng CK, Chan JL, et al.: Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003, 88:2838–2843.

    Article  CAS  PubMed  Google Scholar 

  89. Kanabrocki EL, Hermida RC, Wright M, et al.: Circadian variation of serum leptin in healthy and diabetic men. Chronobiol Int 2001, 18:273–283.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Cardiothoracic Sciences, Second University of Naples, Monaldi Hospital, Naples, Italy

    Paolo Calabrò, Enrica Golia, Lucia Riegler, Giuseppe Limongelli, Paolo Golino, Maria Giovanna Russo & Raffaele Calabrò

Authors
  1. Paolo Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrica Golia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucia Riegler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Limongelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paolo Golino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Giovanna Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raffaele Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Calabrò.

Additional information

Authors Paolo Calabrò and Enrica Golia equally contributed to this review.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calabrò, P., Golia, E., Riegler, L. et al. Inflammation: The Link Between Obesity and Cardiovascular Risk. Curr Cardio Risk Rep 4, 101–111 (2010). https://doi.org/10.1007/s12170-010-0087-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-010-0087-7

Keywords

Search

Navigation